(Information contained in U.S. Food and Drug Administration [FDA] press release dated: January 26, 2021)
The U.S. Food and Drug Administration today announced the following actions taken in its ongoing response effort to the COVID-19 pandemic:
- The agency has updated its FDA COVID-19 Response At-A-Glance Summary, which provides a quick look at facts, figures, and highlights on the FDA's response efforts.
- FDA has posted a CDER Conversation with Katie Gray, Pharm.D., acting director of CDER’s Office of Prescription Drug Promotion (OPDP). This Conversation describes OPDP’s COVID-19 response, which has focused on compliance actions regarding prescription drug promotional materials making false or misleading claims about COVID-19 prevention or treatment. The Conversation also discusses OPDP’s 2020 achievements and 2021 goals, and the way